Phase I, Safety and Immunogenicity of Gardasil in Systemic Lupus Erythematosus
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- Acronyms GARDASIL
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 21 Apr 2017 Status changed from active, no longer recruiting to completed, according to the results published in the Vaccine.
- 09 Apr 2017 Results evaluating the safety and immunogenicity published in the Vaccine.